Biomerica Reports Fiscal 2021 Year End Results
Revenues increase 7.6% for fiscal 2021 vs fiscal 2020. InFoods® IBS Endpoint Trial expected to be fully enrolled in less than 2 weeks. Biomerica receives multiple notices of allowance for …
Biomerica Signs Exclusive Distribution Agreement in Canada
Prevalence of H. pylori infection in the United States is approximately 35% to 40% of the population IRVINE, Calif., June 24, 2021 (GLOBE NEWSWIRE) — Biomerica Inc. (NASDAQ: BMRA) today …
Biomerica Receives Notice of Allowance from Mexican Patent
IBS is one of the most important gastrointestinal disorders in Mexico, with a prevalence of around 16% [1] (approximately 20 million patients) Broadens InFoods® global patent coverage with recently allowed …